# Calquence (acalabrutinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/acalabrutinib

> The FDA approved Calquence (acalabrutinib), sponsored by ASTRAZENECA PLC (AZN), on August 3, 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Calquence (acalabrutinib) |
| Codes | ACP-196 |
| Sponsor | ASTRAZENECA PLC (AZN) https://sec-api.dev/companies/azn/catalysts |
| Indications | [Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma](https://sec-api.dev/indications/chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma), [Diffuse Large B-Cell Lymphoma](https://sec-api.dev/indications/diffuse-large-b-cell-lymphoma), [Chronic Lymphocytic Leukemia (CLL)](https://sec-api.dev/indications/chronic-lymphocytic-leukemia-cll), [Chronic Lymphocytic Leukemia](https://sec-api.dev/indications/chronic-lymphocytic-leukemia), [Mantle Cell Lymphoma (MCL)](https://sec-api.dev/indications/mantle-cell-lymphoma-mcl), [Lymphoma, Mantle Cell](https://sec-api.dev/indications/lymphoma-mantle-cell) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### October 31, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210259 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20171031, review_priority PRIORITY; sponsor_name ASTRAZENECA; product CALQUENCE (ACALABRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210259%22

### August 3, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA216387 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20220803, review_priority STANDARD; sponsor_name ASTRAZENECA; product CALQUENCE (ACALABRUTINIB MALEATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216387%22
- openFDA Drugs@FDA: "NDA216387 ORIG-2 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20220803, review_priority STANDARD; sponsor_name ASTRAZENECA; product CALQUENCE (ACALABRUTINIB MALEATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216387%22

### January 16, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210259 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20250116, review_priority PRIORITY; sponsor_name ASTRAZENECA; product CALQUENCE (ACALABRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210259%22
- openFDA Drugs@FDA: "NDA216387 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20250116, review_priority PRIORITY; sponsor_name ASTRAZENECA; product CALQUENCE (ACALABRUTINIB MALEATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216387%22

### November 4, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Chronic Lymphocytic Leukemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04008706 (Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-04 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-09-01." https://clinicaltrials.gov/study/NCT04008706

### February 19, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210259 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20260219, review_priority STANDARD; sponsor_name ASTRAZENECA; product CALQUENCE (ACALABRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210259%22
- openFDA Drugs@FDA: "NDA216387 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260219, review_priority STANDARD; sponsor_name ASTRAZENECA; product CALQUENCE (ACALABRUTINIB MALEATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216387%22

### September 1, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Chronic Lymphocytic Leukemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04008706 (Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-04 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-09-01." https://clinicaltrials.gov/study/NCT04008706?tab=results

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Lymphoma, Mantle Cell.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02972840 (A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-15 (ESTIMATED); Lead Sponsor Acerta Pharma BV." https://clinicaltrials.gov/study/NCT02972840

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04529772 (A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor Acerta Pharma BV." https://clinicaltrials.gov/study/NCT04529772

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Lymphoma, Mantle Cell.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02972840 (A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-15 (ESTIMATED); Lead Sponsor Acerta Pharma BV." https://clinicaltrials.gov/study/NCT02972840

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04529772 (A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor Acerta Pharma BV." https://clinicaltrials.gov/study/NCT04529772

### Apr to Jul 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Lymphocytic Leukemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03836261 (Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Acerta Pharma BV." https://clinicaltrials.gov/study/NCT03836261

### April 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Lymphocytic Leukemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03836261 (Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Acerta Pharma BV." https://clinicaltrials.gov/study/NCT03836261

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05057494 (A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-15 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05057494

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05057494 (A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-15 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05057494

### Oct 2028 to Jan 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Mantle Cell Lymphoma (MCL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05951959 (A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05951959

### October 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Mantle Cell Lymphoma (MCL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05951959 (A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05951959

### Apr to Jul 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05952024 (Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04-22 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05952024

### April 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05952024 (Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04-22 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05952024

### May 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07024706 (MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-01 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07024706

### May to Aug 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07024706 (MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-01 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07024706

## Same indication

- [APG2575](https://sec-api.dev/pdufa/apg2575) (AAPG)
- [Bexobrutideg](https://sec-api.dev/pdufa/bexobrutideg) (NRIX)
- [Emavusertib](https://sec-api.dev/pdufa/emavusertib) (CRIS)
- [TEPKINLY (epcoritamab)](https://sec-api.dev/pdufa/epcoritamab) (GMAB)
- [Imbruvica (ibrutinib)](https://sec-api.dev/pdufa/ibrutinib) (ABBV)
- [Nemtabrutinib](https://sec-api.dev/pdufa/nemtabrutinib) (MRK)
- [Jaypirca (pirtobrutinib)](https://sec-api.dev/pdufa/pirtobrutinib) (LLY)
- [BEQALZI™ (sonrotoclax)](https://sec-api.dev/pdufa/sonrotoclax) (ONC)
- [Tacabrutideg](https://sec-api.dev/pdufa/tacabrutideg) (ONC)
- [Venclexta (venetoclax)](https://sec-api.dev/pdufa/venetoclax) (ABBV)
- [Zilovertamab vedotin](https://sec-api.dev/pdufa/zilovertamab-vedotin) (MRK)

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02), [April 2027](https://sec-api.dev/fda-calendar/2027-04), [July 2027](https://sec-api.dev/fda-calendar/2027-07), [October 2028](https://sec-api.dev/fda-calendar/2028-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/acalabrutinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Calquence (acalabrutinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/acalabrutinib

```bibtex
@misc{secapidev_pdufa_acalabrutinib_20261116,
  title        = {Calquence (acalabrutinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/acalabrutinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_acalabrutinib_20261116","title":"Calquence (acalabrutinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/acalabrutinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
